Why Hepion Pharmaceuticals Stock Is Soaring Monday
Portfolio Pulse from Adam Eckert
Hepion Pharmaceuticals' stock is soaring after announcing positive results from its Phase 2 ALTITUDE-NASH trial, which met its primary endpoint and demonstrated improved liver function in subjects with stage 3 or greater fibrosis. All secondary endpoints were also met.
May 22, 2023 | 12:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Hepion Pharmaceuticals' stock is soaring after positive Phase 2 ALTITUDE-NASH trial results, which met primary and secondary endpoints, demonstrating improved liver function.
The positive results from Hepion Pharmaceuticals' Phase 2 ALTITUDE-NASH trial indicate that the company's drug development is progressing well, which is likely to boost investor confidence and drive the stock price up in the short term. The trial met its primary endpoint and all secondary endpoints, demonstrating improved liver function in subjects with stage 3 or greater fibrosis.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100